Engflag

Calvit Tablet

Quick links to important sections

Calvit Tablet

Calvit Tablet_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calvit Tablet

What is Calvit Tablet? Definition and Composition

Property Description
Active Ingredients Calcium Carbonate & Cholecalciferol (Vitamin D3)
Form Oral Tablet
Pharmacological Class Mineral and Vitamin Supplement
Common Use Treating/Preventing Calcium and Vitamin D Deficiencies
Origin Synthetic/Semi-Synthetic

The Calvit Tablet is a widely available, orally administered nutritional supplement formulated to help the body manage essential mineral and vitamin balance, primarily supporting bone health. As a solid oral dosage form, the tablet is designed for convenient ingestion. Calvit is manufactured by various pharmaceutical companies and is marketed as an accessible supplement for calcium and Vitamin D deficiencies.

Calvit Tablet's Core Ingredients and Classification

Calvit Tablet primarily contains Calcium (usually as Calcium Carbonate) and Cholecalciferol (Vitamin D3) as its key active ingredients. These components classify the preparation within the pharmacological class of Mineral and Vitamin Supplements (specifically, a Calcium/Cholecalciferol combination). Its components are typically manufactured through synthetic or semi-synthetic processes to ensure consistent purity and potency.

This specific combination is clinically recognized for its essential role in skeletal health. This combination is used to prevent or treat low blood calcium in people who do not get enough calcium from their diets.

Why is Calvit Tablet Used? General Therapeutic Purpose

The general therapeutic purpose of Calvit Tablet is to address or prevent conditions that arise from inadequate intake or absorption of calcium and Vitamin D, which are critical for maintaining healthy bone mineral density. A common use scenario involves adults, especially those prone to a natural decrease in bone mineral density, such as women over 40.

Vitamin D's primary function is to help the body absorb calcium, which is why they are often combined in supplements. By reliably supplying these key nutrients, Calvit assists in the long-term maintenance of good bone health and helps regulate fundamental physiological processes dependent on optimal calcium levels.

Regulatory References

  1. Cholecalciferol (Vitamin D3) - MedlinePlus Drug Information
  2. Vitamin and Mineral Supplements - Nutrition.gov

What side effects are possible with Calvit Tablet?

Possible side effects and safety information

The safety profile for Calcium Carbonate and Cholecalciferol (Calvit Tablet) is defined by its potential to affect mineral balance, as documented by regulatory authorities. The adverse effects are officially classified by the physiological system involved and their expected frequency.

Adverse Reaction Classifications

The most clinically significant effects are related to the accumulation of calcium:

  • Uncommon (1/1,000 to < 1/100): Hypercalcaemia (elevated blood calcium) and hypercalciuria (elevated urinary calcium). These are the primary metabolic risks.
  • Rare (1/10,000 to < 1/1,000): Gastrointestinal disorders such as constipation, flatulence, abdominal pain, and nausea. Skin and subcutaneous tissue disorders, including rash and urticaria (hives), have also been documented.

Serious Adverse Reactions and Dose-Related Risk

While rare, the official documentation lists serious reactions, typically associated with high doses or long-term overdose. These include Milk-alkali syndrome (Burnett syndrome), which is a combination of high blood calcium, metabolic alkalosis, and impaired kidney function, and the potential for vascular and soft tissue calcification.

Safety Restrictions and Special Populations

The medicine is strictly contraindicated in conditions involving pre-existing high calcium levels (hypercalcaemia or hypercalciuria) and in individuals with severe renal insufficiency (poor kidney function) or a history of nephrolithiasis (kidney stones). Specific cautions apply to certain groups: use requires careful monitoring in patients with renal impairment, in older adults, and in immobilised patients with osteoporosis due to the heightened risk of hypercalcaemia.

The regulatory safety structure focuses on controlling the risk of mineral overaccumulation and ensuring that the medicine is not used in patients whose conditions already present a heightened risk of high calcium levels.

Overdose and Emergency Response

The official regulatory overdose profile for Calvit Tablet (Calcium Carbonate and Cholecalciferol) is defined by the development of Hypervitaminosis D and resulting Hypercalcemia (elevated serum calcium levels), which is the primary cause of toxicity.

Overdose Scope

Category Official Regulatory Statement
Documented overdose presentations Initial manifestations include Anorexia, Nausea, Vomiting, Constipation, Polyuria, Polydipsia, Weakness, Fatigue, and Confusion.
Physiological systems affected Renal (Acute renal failure, Nephrocalcinosis), Cardiovascular (Arrhythmias), and Central Nervous System (Stupor, Coma).
Population-specific overdose notes Overdose must be avoided during pregnancy due to the risk of fetal complications. Caution is required for patients with renal impairment.
When immediate medical help is required Seek immediate medical attention or call emergency services if severe symptoms like persistent vomiting, seizure, or severe confusion are present.

Emergency Action and Treatment

Category Official Regulatory Statement
Mandated Emergency Action The supplement must be immediately discontinued.
Antidote Information No specific antidote is known; management is symptomatic and supportive.
Monitoring Requirements Required monitoring includes frequent assessment of serum calcium, renal function (Creatinine), and ECG due to the risk of cardiac involvement.

Connection to the Official Profile

Regulatory documents define this overdose profile by establishing the toxicity (Hypercalcemia) and listing specific manifestations. These documents explicitly mandate that the supplement must be immediately stopped and specify the conditions (such as severe vomiting or CNS changes) under which patients must contact emergency medical services. The profile highlights the required supportive measures and the lack of a specific antidote.

Therapeutic Uses of Calvit Tablet

What Calvit Tablet treats: Main Uses and Benefits

Calvit (Calcium Carbonate and Vitamin D3) is commonly used to address symptoms linked to organ-specific functional stress related to bone and mineral health. Its primary role supports the body in maintaining strong bones and is often applied in scenarios where additional management of discomfort is required due to mineral deficiency. The combination may assist with the prevention and is considered relevant for easing symptoms related to inflammatory or irritative states linked to weakened bones.

These tablets are commonly used across conditions presenting with acute episodes, including osteoporosis (thinning of bones) and rickets (bone weakening in children). This supportive management contributes to improved functional stability during symptomatic phases.

“The combination provides support that helps ease the overall symptom burden associated with calcium and vitamin D deficiencies.”

This assistance helps with managing conditions where symptoms may intensify temporarily, providing supportive relief when symptoms interfere with routine activities. The combination may be part of symptomatic management applied in contexts involving heightened systemic burden.

Quick Fact: Supports patients during episodes of heightened discomfort

Regulatory References

  1. Vitamin D - MedlinePlus overview

Eligibility and Restrictions for Use

The official eligibility profile for Calvit Tablet (Calcium Carbonate and Cholecalciferol) is defined by regulatory bodies based on the patient's existing mineral status and certain comorbidities. Use is typically allowed for adults and the elderly requiring supplementation for calcium and Vitamin D deficiencies.

Contraindicated Populations (Must Not Use)

The medicine is contraindicated (prohibited) for individuals with absolute conditions that pose a risk of mineral overload, including:

  • Hypercalcaemia (high calcium in the blood) or Hypercalciuria (high calcium in the urine).
  • Hypervitaminosis D (excessive accumulation of Vitamin D).
  • Severe Renal Impairment or a history of Nephrolithiasis (kidney stones).

Restricted and Conditional Use

Population/Condition Regulatory Status
Pregnancy/Lactation Permitted only under a strict daily Vitamin D dose limit (e.g., typically not exceeding 600 IU) to avoid maternal/fetal harm [Source: SmPC equivalent].
Children/Adolescents Use of high-dose formulations is restricted or not indicated due to excessive Vitamin D concentration.
Sarcoidosis Requires caution and monitoring of calcium levels due to an increased risk of hypercalcaemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Calvit Tablet, a combination of Calcium Carbonate and Cholecalciferol (Vitamin D3), has documented interaction patterns that are classified as pharmacokinetic and pharmacodynamic in regulatory labeling. The co-administration of other Vitamin D products is formally restricted due to the significant additive risk of hypervitaminosis D and hypercalcaemia.

Documented Exposure and Pharmacodynamic Effects

Interacting Substance/Class Official Interaction Outcome
Tetracycline & Quinolone Antibiotics Calcium salts may officially reduce the absorption and systemic exposure of the antibiotic.
Thyroxine, Bisphosphonates, Iron Supplements Calcium salts may officially reduce the absorption of these agents, requiring dose separation.
Thiazide Diuretics Increased risk of hypercalcaemia due to reduced renal excretion of calcium.
Cardiac Glycosides (e.g., Digitalis) Effects may be accentuated, increasing the risk of cardiac arrhythmias.
Phenytoin or Barbiturates May officially decrease the effect of Vitamin D due to metabolic activation.

To mitigate reduced absorption, mandatory timing separation requirements are officially advised. For example, co-administration with levothyroxine requires a separation of at least four hours. Interactions with food, such as those high in oxalic or phytic acid (e.g., spinach, whole grains), may also officially decrease calcium absorption and require dose spacing. The use of this combination is formally contraindicated in patients with severe renal impairment due to heightened interaction outcomes.

Mechanism of Action

Modulating Intestinal Absorption of Calcium

Calvit Tablet, a combination of Calcium and Vitamin D3 (Cholecalciferol), influences mineral homeostasis by modulating key absorption pathways. The active form of Vitamin D3, Calcitriol, interacts with the Vitamin D receptor (VDR) in the gastrointestinal tract. This interaction initiates signaling sequences that increase the expression of calcium-binding proteins, leading to an amplified absorption of dietary calcium and phosphate from the small intestine. This pathway adjustment influences the net influx of calcium into the circulation, a downstream physiological consequence of enhanced intestinal absorption.

Regulation of Systemic Calcium Dynamics

The formulation engages mechanisms that influence the dynamic balance of calcium movement, affecting its deposition and mobilization within bone tissue, which acts as the body's primary storage reservoir. Furthermore, the provision of calcium modulates calcium-dependent processes crucial for excitable cell function. Calcium acts as an essential ion and crucial second messenger in pathways necessary for nerve conduction and muscle cell activity, thereby modulating overall systemic physiological processes.

Dosage and Administration Information

Administration Protocol and Official Regimens

Calvit Tablet, a combination of Calcium Carbonate and Cholecalciferol (Vitamin D3), is authorized for oral administration. The specific method of intake depends on the tablet form: chewable tablets must be chewed or sucked completely before swallowing, while film-coated tablets should be swallowed whole with a glass of water or juice.

Labeled Dosing and Frequency

The standard regimen for adults and the elderly, used for supplementation and as an adjunct to osteoporosis therapy, is typically one to two tablets daily. This high-level instruction establishes the range for the daily amount of elemental calcium and Vitamin D3 intake from the product. Frequency is scheduled as once daily or twice daily (often morning and evening), depending on the specific strength of the tablet used in the regimen.

Administration is generally advised as a long-term treatment regimen. Certain formulations advise taking the dose with or close to a meal; other formulations may be taken independently of food. To prevent reduced absorption, the administration of Calvit must be separated by several hours from certain other oral medications.

Population Context and Procedural Structure

The usage protocol for older adults aligns with the standard adult regimen. Specific combination products are generally not recommended for use in pediatric populations. Patients with any degree of renal impairment require careful monitoring of serum and urinary calcium levels while on this regimen. The overall procedural structure defines the correct sequence: identifying the correct form, administering the dose via chewing or swallowing, and adhering to the prescribed daily frequency and necessary time-separation from other oral drugs.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Calvit Tablet

Evidence for Use in Contexts Related to Osteoporosis and Bone Thinning

Research on the components of Calvit Tablet (Calcium and Vitamin D3) was studied for its potential role in contexts related to osteoporosis and bone thinning. The evidence base for these components includes Randomized Controlled Trials (RCTs) and comprehensive reviews, which aggregate data from many separate trials. These studies have used in research exploring how symptoms change over time, particularly over long periods.

In these trials, research examined two key types of outcomes: changes in Bone Mineral Density (BMD), measured at sites like the hip and spine, and the incidence of bone fractures. The populations studied included large groups of postmenopausal women and community-dwelling older adults, as well as highly specialized groups like institutionalized individuals.

Findings describe patterns observed in the studies where supplementation was associated with changes in BMD measurements across several study populations, indicating a change in mineral density within the measured bone segments. For the broader population of older adults living independently, findings were mixed across various meta-analyses. Evidence is limited regarding a consistent effect on fracture prevention in every community-dwelling individual, suggesting that results may depend on the person's baseline nutrient status.

Evidence for Use in Correcting Nutritional Deficiencies (Rickets/Osteomalacia)

The role of Calcium and Vitamin D in addressing severe nutritional deficiencies, namely rickets in children and osteomalacia in adults, was studied for many decades, contributing to the evidence landscape. Due to the severe nature of these deficiencies, evidence is derived from settings with varying symptom burdens, including historical data, modern case series, and trials in severely affected populations.

Studies explored outcomes linked to the signs of deficiency. For children with rickets, research has explored the outcomes related to systemic or functional imbalance by monitoring radiographic changes (visible on X-ray) and normalization of serum biomarkers (such as calcium and phosphorus levels). Findings describe patterns observed in the studies where changes in biochemical abnormalities were monitored following the administration of the combined nutrients in deficient populations.

What Remains Undocumented or Uncertain

Scientific reviews highlight several areas where research is ongoing and certainty remains low. One major area of uncertainty is not yet clear is the precise difference observed when supplementing individuals whose nutrient levels are considered only mildly insufficient, rather than severely deficient. Evidence quality varies across studies, particularly when moving from severe deficiency treatment (where evidence is high) to broad-based fracture prevention (where evidence is moderate and heterogeneous). Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Calvit Tablet (FAQ)

Q: How long does it take for Calvit Tablet to start working?

Label information indicates that patients may experience an improvement in symptoms within 4 to 6 weeks of starting Calvit Tablet. It is a gradual process, and for some, it may take up to 3 months to feel a noticeable benefit. Continue taking Calvit Tablet as prescribed, and discuss any desire to stop treatment with your healthcare provider.

Q: Can I drink alcohol while taking Calvit Tablet?

It is generally recommended to limit or avoid alcohol while taking Calvit Tablet. Combining alcohol with this medication may increase the risk of central nervous system side effects such as dizziness and drowsiness. The product label suggests minimizing alcohol intake, as doing so is associated with a lower risk of interaction.

Q: What should I do if I miss a dose of Calvit Tablet?

The general recommendation is to take the missed dose as soon as you remember. However, if it is nearly time for the next scheduled dose, it is generally advised to skip the missed dose and resume your regular schedule. Do not double the dose, as this may increase the risk of side effects or adverse events. Consult the specific instructions provided by your prescriber for personalized guidance on missed doses.

How should Calvit Tablet be stored and disposed of?

The storage and disposal of Calvit Tablets must strictly follow conditions detailed in official regulatory documentation to maintain product stability and safety.

Official Storage Requirements

Condition Type Requirement
Temperature Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). Do not expose to excessive heat.
Environmental Protect from moisture and humidity. Store in a cool dry place.
Container Keep the product in its original container with the closure tightly closed. Do not use if the safety seal is broken or missing.
Child Safety Keep out of the reach of children.

Official Disposal Rules

Expired or unused Calvit Tablets must be disposed of according to local regulations. Regulatory agencies advise against disposal via wastewater (flushing or pouring down the drain) or routine household trash to protect the environment. Consult a pharmacist or local waste authority for authorized take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Calvit Tablet found in:

A-Z Index: